William (Bill) Rauwerdink

The All-Access Pass to Owning Your Fandom #FLOW #NFT

In 2014, an ER department physician shared his frustration with the inability of traditional vital signs to detect and predict patient destabilization that can lead to crisis. That challenged our team of nurses, physicians, and scientists to put the power of advanced signal processing and clinician supervised machine learning to work to break the code of the autonomic nervous system. The result was the AHI System – the only FDA-cleared clinical decision support device of its kind, predicting episodes of hemodynamic instability with clinically significant lead times, and giving care teams the time to plan and intervene to avoid a costly crisis, improve patient throughput and increase the overall effectiveness of telemetry monitoring. AHI, or Analytic for Hemodynamic Instability, was developed using artificial intelligence to see Heart Rate Variability (HRV), part of the autonomic nervous system (ANS). Fifth Eye discovered how to measure and interpret HRV data flow and ECG morphology features, predicting the hemodynamic risk that leads to acute decline in clinical status. Traditional vitals like blood pressure and pulse rate are “lagging indicators”, unable to see hours or days into the future to identify patients who may be at risk from compromised compensatory systems. AHI works on a single, noninvasive ECG lead II, displaying patient status updates every two minutes from anywhere in the hospital. There are no manual inputs, no new hardware and AHI is easy to adopt and use immediately. AHI is making a difference in the lives of patients and clinical teams – getting ahead of vitals to help patients on the brink of crisis receive care sooner and enhancing throughput to downgrade or discharge stable patients sooner. To learn more, visit FIFTHeye.com The AHI System is intended for use by healthcare professionals managing patients 18 years or older who are receiving continuous physiological monitoring with electrocardiography (ECG) in hospitals.

Gemphire is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. We are developing our product candidate gemcabene (CI 1027), a novel, once daily, oral therapy, for patients who are unable to achieve normal levels of LDL C or triglycerides with currently approved therapies, primarily statin therapy. Gemcabene’s mechanism of action is designed to enhance the clearance of very low density lipoproteins (VLDLs) in the plasma and inhibit the production of fatty acids and cholesterol in the liver. The Gemphire team is also exploring the utility of gemcabene in Nonalcoholic Steatohepatitis (NASH) and/or Nonalcoholic Fatty Liver Disease (NAFLD) given its mechanism of action that decreases the production of the apoC III protein and may inhibit ACC, which has been observed to result in the lowering of triglycerides in the plasma and may reduce liver fat. We are focused on a broad spectrum of indications for dyslipidemia patients ranging from the orphan indication HoFH to more prevalent conditions, such as HeFH, ASCVD and SHTG. In the next twelve months, we plan to initiate three late stage clinical trials with early results expected starting at the end of 2016 continuing through the first half of 2018.

Invented in 2010 by three undergrad juniors in between midterms and term papers, EatStreet was built to be the smartest shortcut to the food you crave. Based in Madison, WI, EatStreet is the largest independent food ordering service in the United States offering food delivery and takeout from over 15,000 restaurants in over 250 cities. Hungry for more details? Visit eatstreet.com!

Advisor HR is a Professional Employer Organization (PEO) dedicated to empowering businesses nationwide through comprehensive Human Capital Management (HCM) solutions. We specialize in streamlining HR processes, payroll management, compliance, and benefits administration, enabling our clients to focus on their core operations. Our partnerships with P&C firms, benefits agencies, ancillary partners, CPAs, and wealth management professionals allow us to deliver tailored services that meet each partners clients unique needs. Advisor HRs inspiring story began in 2014 with a vision to make a meaningful impact on companies through PEO services, offering clients a personalized, boutique experience. With best-in-class technology and exceptional client services that make a true difference, Advisor HR has, through its unwavering commitment to excellence and quality, carved out a unique niche in the highly competitive PEO industry.

Celsee, Inc., is harnessing the gentle power of gravity to break down barriers in single-cell analysis. Our technology’s unparalleled capture and viability rates, plus the ability to scale easily to millions of cells, deliver high-confidence results for applications such as single-cell cytometry, proteogenomics, transcriptomics, and rare-cell enumeration. With Celsee’s Genesis system, users can achieve accurate biological insight by capturing more cells, because every cell matters. Celsee is a privately held company based in Ann Arbor, Michigan.

Since 1917, Chemical Banks hometown approach to banking has remained steadfast and focused on community banking, highlighted by local leadership and decision making, a devotion to community and personalized service. We are committed to delivering the guidance and support you need to plan for the future and reach your financial goals. Using a team approach, we provide you with an array of expertise that spans business, personal and investment services. Our experienced professionals spend much of their time working closely with you, and learning about your goals in order to develop financial solutions that will help you meet your needs. A DIVISION OF TCF NATIONAL BANK | MEMBER FDIC | EQUAL HOUSING LENDER

Consultative solutions for single-cell, high resolution cytogenetic analysis to enable today’s most innovative developments in cell and gene therapy.

The All-Access Pass to Owning Your Fandom #FLOW #NFT

In 2014, an ER department physician shared his frustration with the inability of traditional vital signs to detect and predict patient destabilization that can lead to crisis. That challenged our team of nurses, physicians, and scientists to put the power of advanced signal processing and clinician supervised machine learning to work to break the code of the autonomic nervous system. The result was the AHI System – the only FDA-cleared clinical decision support device of its kind, predicting episodes of hemodynamic instability with clinically significant lead times, and giving care teams the time to plan and intervene to avoid a costly crisis, improve patient throughput and increase the overall effectiveness of telemetry monitoring. AHI, or Analytic for Hemodynamic Instability, was developed using artificial intelligence to see Heart Rate Variability (HRV), part of the autonomic nervous system (ANS). Fifth Eye discovered how to measure and interpret HRV data flow and ECG morphology features, predicting the hemodynamic risk that leads to acute decline in clinical status. Traditional vitals like blood pressure and pulse rate are “lagging indicators”, unable to see hours or days into the future to identify patients who may be at risk from compromised compensatory systems. AHI works on a single, noninvasive ECG lead II, displaying patient status updates every two minutes from anywhere in the hospital. There are no manual inputs, no new hardware and AHI is easy to adopt and use immediately. AHI is making a difference in the lives of patients and clinical teams – getting ahead of vitals to help patients on the brink of crisis receive care sooner and enhancing throughput to downgrade or discharge stable patients sooner. To learn more, visit FIFTHeye.com The AHI System is intended for use by healthcare professionals managing patients 18 years or older who are receiving continuous physiological monitoring with electrocardiography (ECG) in hospitals.